Cyrus Biotechnology is a Seattle-based computational protein design company that engineers biologics from natural proteins for therapeutic indications.
Cyrus Biotechnology is a Seattle-based biotechnology company that uses computational protein design and large-scale deep mutagenesis scanning to engineer biologics from naturally occurring proteins. Its platform combines AI and Rosetta-based design methods with laboratory screening for immunogenicity reduction, half-life extension, stability, solubility, and affinity optimization, and the company has applied these capabilities across more than thirty partnered discovery programs with pharmaceutical and biotechnology partners.
Its internal and partnered pipeline includes an engineered IgG-degrading protease whose clinical candidate CYR212 was selected for chronic IgG-driven autoimmune disease, an IL-22 fusion protein resistant to IL-22 binding protein, an IL-15 oncology candidate, an ACE2-Fc fusion candidate for acute respiratory distress syndrome, and a cytomegalovirus receptor decoy program. In 2024 the company spun out its software and services group as Levitate Bio, and it co-founded the OpenFold consortium in 2022.
Cyrus IdeS (CYR212) is an engineered IgG-degrading protease designed to rapidly deplete pathogenic IgG autoantibodies in IgG-mediated autoimmune diseases.
Cyrus Platform is Cyrus Biotechnology's computational protein design offering combining AI and Rosetta-based design with laboratory mutagenesis screening.
